Overview of atherosclerosis

Clinical Therapeutics

Volumn 20, Issue SUPPL.2, 1998, Pages

  Kannel, William B ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Mortality; Prevention; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; CORONARY RISK; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIMARY PREVENTION; REVIEW; STROKE; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ARTERIOSCLEROSIS; COMORBIDITY; COST OF ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROGNOSIS; RISK FACTORS; UNITED STATES;

EID: 0031803825     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80027-1     Document Type: Article

References (19)

1. Kannel WB, Thorn TJ. Incidence, prevalence and mortality of cardiovascular diseases. In: Schlant RC, Alexander RW, eds. The Heart. 8th ed. New York: McGraw-Hill; 1994:185-197.
2. National Heart, Lung, and Blood Institute. Morbidity and Mortality 1996 Chartbook on Cardiovascular, Lung and Blood Diseases. Washington, DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 1996.
3. Kannel WB. The demographics of claudication and the aging of the American population. Vasc Med. 1996;1:60-64.
4. Cupples LA, D'Agostino RB. The Framingham Heart Study, Section 35: Survival Following Initial Cardiovascular Events: 30 Year Follow-Up. Washington, DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 1988.
5. American Heart Association. Heart and Stroke Facts: 1997 Statistical Supplement. Dallas, Tex: American Heart Association; 1997.
6. Kannel WB. Epidemiologic relationship of disease among the different vascular territories. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven; 1996;II:1591-1599.
7. Cupples LA, Gagnon DR, Wong ND, et al. Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: The Framingham Heart Study. Am Heart J. 1993;125: 863-872.
8. Kannel WB, McGee DL. Update on some epidemiologic features of intermittent claudication: The Framingham Heart Study. J Am Geriatr Soc. 1985;33:13-18.
9. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-362.
10. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: A risk profile from the Framingham Heart Study. Stroke. 1991;22:312-318.
11. Murabito JM, D'Agostino RB, Silbershatz H, Wilson PWF. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation. 1997;96:44-49.
12. Reaven GM. Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu Rev Med. 1993; 44:121-131.
13. Manson JE, Tosteson H, Ridker PM, et al. The primary prevention of myocardial infarction. NEJM. 1992;326:1406-1416.
14. Rich-Edwards JW, Manson JE, Hennekens CM, Buring JE. The primary prevention of coronary heart disease in women. NEJM. 1995;332:1758-1766.
15. Bittner V. Primary and secondary prevention of ischemic heart disease. Curr Opin Cardiol. 1994;9:417-427.
16. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
17. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEJM. 1996;335:1001-1009.
18. Hennekens CM, Peto K, Hutchison GB, Doll R. An overview of the British and American aspirin studies. NEJM. 1988; 318:923-924.
19. Nieto FJ, Alonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia. The Atherosclerosis Risk in Communities Study. Arch Intern Med. 1995;155: 677-684.